Working… Menu

Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02553642
Recruitment Status : Active, not recruiting
First Posted : September 17, 2015
Last Update Posted : July 31, 2019
UConn Health
Bristol-Myers Squibb
Adaptive Biotechnologies
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center